Last reviewed 2026-05-26 · How we verify

Clindamycin 1% lotion formulation:

Centre for Human Drug Research, Netherlands · Phase 1 active Small molecule ✓ Verified May 2026

Clindamycin 1% lotion formulation: is a Small molecule drug developed by Centre for Human Drug Research, Netherlands. It is currently in Phase 1 development.

Clindamycin 1% lotion formulation is a topical antibiotic used to treat conditions such as acne vulgaris and inflammation. It works by inhibiting the bacterial 70S ribosome, a mechanism that is consistent with its classification as a small molecule inhibitor.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Clindamycin 1% lotion formulation:
Sponsor	Centre for Human Drug Research, Netherlands
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clindamycin 1% lotion formulation: CI brief — competitive landscape report
Clindamycin 1% lotion formulation: updates RSS · CI watch RSS
Centre for Human Drug Research, Netherlands portfolio CI

Frequently asked questions about Clindamycin 1% lotion formulation:

What is Clindamycin 1% lotion formulation:?

Clindamycin 1% lotion formulation: is a Small molecule drug developed by Centre for Human Drug Research, Netherlands.

Who makes Clindamycin 1% lotion formulation:?

Clindamycin 1% lotion formulation: is developed by Centre for Human Drug Research, Netherlands (see full Centre for Human Drug Research, Netherlands pipeline at /company/centre-for-human-drug-research-netherlands).

What development phase is Clindamycin 1% lotion formulation: in?

Clindamycin 1% lotion formulation: is in Phase 1.

Manufacturer: Centre for Human Drug Research, Netherlands — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing